» Articles » PMID: 12923173

Complementary Roles of Farnesoid X Receptor, Pregnane X Receptor, and Constitutive Androstane Receptor in Protection Against Bile Acid Toxicity

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2003 Aug 19
PMID 12923173
Citations 111
Authors
Affiliations
Soon will be listed here.
Abstract

The nuclear receptors, farnesoid X receptor (FXR) and pregnane X receptor (PXR), are important in maintaining bile acid homeostasis. Deletion of both FXR and PXR in vivo by cross-breeding B6;129-Fxrtm1Gonz (FXR-null) and B6;129-Pxrtm1Glaxo-Wellcome (PXR-null) mice revealed a more severe disruption of bile acid, cholesterol, and lipid homeostasis in B6;129-Fxrtm1Gonz Pxrtm1Glaxo-Wellcome (FXR-PXR double null or FPXR-null) mice fed a 1% cholic acid (CA) diet. Hepatic expression of the constitutive androstane receptor (CAR) and its target genes was induced in FXR- and FPXR-null mice fed the CA diet. To test whether up-regulation of CAR represents a means of protection against bile acid toxicity to compensate for the loss of FXR and PXR, animals were pretreated with CAR activators, phenobarbital or 1,4-bis[2-(3,5-dichlorpyridyloxy)]benzene (TCPOBOP), followed by the CA diet. A role for CAR in protection against bile acid toxicity was confirmed by a marked reduction of serum bile acid and bilirubin concentrations, with an elevation of the expression of the hepatic genes involved in bile acid and/or bilirubin metabolism and excretion (CYP2B, CYP3A, MRP2, MRP3, UGT1A, and glutathione S-transferase alpha), following pretreatment with phenobarbital or TCPOBOP. In summary, the current study demonstrates a critical and combined role of FXR and PXR in maintaining not only bile acid but also cholesterol and lipid homeostasis in vivo. Furthermore, FXR, PXR, and CAR protect against hepatic bile acid toxicity in a complementary manner, suggesting that they serve as redundant but distinct layers of defense to prevent overt hepatic damage by bile acids during cholestasis.

Citing Articles

Up-to-Date Snapshot of Current and Emerging Medical Therapies in Primary Biliary Cholangitis.

Warsop Z, Anand N, Al Maliki H, De Souza S, Kamyab A, Al Hadad A J Pers Med. 2024; 14(12).

PMID: 39728045 PMC: 11678846. DOI: 10.3390/jpm14121133.


Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development.

Li T, Chiang J Pharmacol Rev. 2024; 76(6):1221-1253.

PMID: 38977324 PMC: 11549937. DOI: 10.1124/pharmrev.124.000978.


Another renaissance for bile acid gastrointestinal microbiology.

Ridlon J, Gaskins H Nat Rev Gastroenterol Hepatol. 2024; 21(5):348-364.

PMID: 38383804 PMC: 11558780. DOI: 10.1038/s41575-024-00896-2.


Distinct bile acid alterations in response to a single administration of PFOA and PFDA in mice.

Yu X, Zhang Y, Cogliati B, Klaassen C, Kumar S, Cheng X Toxicology. 2024; 502:153719.

PMID: 38181850 PMC: 10922993. DOI: 10.1016/j.tox.2023.153719.


Pharmacological activation of constitutive androstane receptor induces female-specific modulation of hepatic metabolism.

Huillet M, Lasserre F, Gratacap M, Engelmann B, Bruse J, Polizzi A JHEP Rep. 2023; 6(1):100930.

PMID: 38149074 PMC: 10749885. DOI: 10.1016/j.jhepr.2023.100930.